These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19363257)

  • 21. Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein.
    Cole GM; Ard MD
    Microsc Res Tech; 2000 Aug; 50(4):316-24. PubMed ID: 10936886
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Apolipoprotein E and Alzheimer disease.
    Huang Y
    Neurology; 2006 Jan; 66(2 Suppl 1):S79-85. PubMed ID: 16432152
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology.
    Hartman RE; Wozniak DF; Nardi A; Olney JW; Sartorius L; Holtzman DM
    Exp Neurol; 2001 Aug; 170(2):326-44. PubMed ID: 11476599
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Apolipoprotein E genotype and alpha-tocopherol modulate amyloid precursor protein metabolism and cell cycle regulation.
    Huebbe P; Schaffer S; Jofre-Monseny L; Boesch-Saadatmandi C; Minihane AM; Müller WE; Eckert GP; Rimbach G
    Mol Nutr Food Res; 2007 Dec; 51(12):1510-7. PubMed ID: 18030662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid-beta deposition in vivo.
    Fagan AM; Holtzman DM
    Microsc Res Tech; 2000 Aug; 50(4):297-304. PubMed ID: 10936884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks.
    Bour A; Grootendorst J; Vogel E; Kelche C; Dodart JC; Bales K; Moreau PH; Sullivan PM; Mathis C
    Behav Brain Res; 2008 Nov; 193(2):174-82. PubMed ID: 18572260
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies.
    Huang Y
    Curr Opin Drug Discov Devel; 2006 Sep; 9(5):627-41. PubMed ID: 17002223
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Independent effects of APOE on cholesterol metabolism and brain Abeta levels in an Alzheimer disease mouse model.
    Mann KM; Thorngate FE; Katoh-Fukui Y; Hamanaka H; Williams DL; Fujita S; Lamb BT
    Hum Mol Genet; 2004 Sep; 13(17):1959-68. PubMed ID: 15229191
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of apolipoproteins E3 and E4 on the transforming growth factor-β system in targeted replacement mice.
    Haas A; Liraz O; Michaelson DM
    Neurodegener Dis; 2012; 10(1-4):41-5. PubMed ID: 22301441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model.
    Holtzman DM; Fagan AM; Mackey B; Tenkova T; Sartorius L; Paul SM; Bales K; Ashe KH; Irizarry MC; Hyman BT
    Ann Neurol; 2000 Jun; 47(6):739-47. PubMed ID: 10852539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RAGE does not affect amyloid pathology in transgenic ArcAbeta mice.
    Vodopivec I; Galichet A; Knobloch M; Bierhaus A; Heizmann CW; Nitsch RM
    Neurodegener Dis; 2009; 6(5-6):270-80. PubMed ID: 20145420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-amyloid expression, release and extracellular deposition in aged rat brain slices.
    Marksteiner J; Humpel C
    Mol Psychiatry; 2008 Oct; 13(10):939-52. PubMed ID: 17712316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced levels of human apoE4 protein in an animal model of cognitive impairment.
    Sullivan PM; Han B; Liu F; Mace BE; Ervin JF; Wu S; Koger D; Paul S; Bales KR
    Neurobiol Aging; 2011 May; 32(5):791-801. PubMed ID: 19577821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Apolipoprotein gene and its interaction with the environmentally driven risk factors: molecular, genetic and epidemiological studies of Alzheimer's disease.
    Lahiri DK; Sambamurti K; Bennett DA
    Neurobiol Aging; 2004; 25(5):651-60. PubMed ID: 15172744
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum.
    Belinson H; Michaelson DM
    J Neural Transm (Vienna); 2009 Nov; 116(11):1427-34. PubMed ID: 19370389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. APOE ε4: the most prevalent yet understudied risk factor for Alzheimer's disease.
    Michaelson DM
    Alzheimers Dement; 2014 Nov; 10(6):861-8. PubMed ID: 25217293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification and modification of amyloid-independent phenotypes of APOE4 mice.
    DiBattista AM; Dumanis SB; Newman J; Rebeck GW
    Exp Neurol; 2016 Jun; 280():97-105. PubMed ID: 27085394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The nucleation growth and reversibility of Amyloid-beta deposition in vivo.
    Dolev I; Michaelson DM
    J Alzheimers Dis; 2006 Nov; 10(2-3):291-301. PubMed ID: 17119294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An Anti-apoE4 Specific Monoclonal Antibody Counteracts the Pathological Effects of apoE4 In Vivo.
    Luz I; Liraz O; Michaelson DM
    Curr Alzheimer Res; 2016 Jun; 13(8):918-29. PubMed ID: 27040139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brain changes may develop early in people with Alzheimer's risk marker. Changes in brain activity appear to occur before amyloid plaques emerge in people with a form of the APOE4 gene.
    Duke Med Health News; 2011 Mar; 17(3):3. PubMed ID: 21476240
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.